DFTX Definium Therapeutics Inc.

Price (delayed)

$37.65

Market cap

$5.06B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$3.43

Enterprise value

$4.44B

Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 0
Highlights
DFTX's quick ratio is up by 50% from the previous quarter and by 43% YoY
The debt has declined by 11% year-on-year and by 11% since the previous quarter
The company's EPS has shrunk by 150% YoY and by 38% QoQ
The net income has declined by 49% since the previous quarter

Key stats

What are the main financial stats of DFTX

DFTX stock price

How has the Definium Therapeutics stock price performed over time
Intraday
-6.62%
1 week
-0.53%
1 month
-16.17%
1 year
278.39%
YTD
181.18%
QTD
-19.96%

Financial performance

How have Definium Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$227.54M
Net income
-$353.79M
Gross margin
N/A
Net margin
N/A
The operating income has dropped by 75% year-on-year and by 18% since the previous quarter
The net income has declined by 49% since the previous quarter

Price vs fundamentals

How does DFTX's price correlate with its fundamentals

Growth

What is Definium Therapeutics's growth rate over time

Valuation

What is Definium Therapeutics stock price valuation
P/E
N/A
P/B
4.47
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The company's EPS has shrunk by 150% YoY and by 38% QoQ
The P/B is 65% above the 5-year quarterly average of 2.9 but 17% below the last 4 quarters average of 5.8

Efficiency

How efficient is Definium Therapeutics business performance
The ROE has dropped by 70% year-on-year but it is up by 17% since the previous quarter
Definium Therapeutics's ROIC has plunged by 65% YoY and by 29% from the previous quarter
DFTX's ROA has plunged by 64% YoY but it is up by 9% from the previous quarter

Dividends

What is DFTX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for DFTX.

Financial health

How did Definium Therapeutics financials performed over time
Definium Therapeutics's total assets has soared by 177% from the previous quarter
The total liabilities has soared by 144% YoY and by 59% from the previous quarter
The debt is 96% smaller than the equity
Definium Therapeutics's debt to equity has plunged by 82% YoY and by 73% from the previous quarter
The debt has declined by 11% year-on-year and by 11% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.